Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease

被引:3
|
作者
Tajima, Naoyuki
Nagashima, Satoru
Uematsu, Toshihiko
Torii, Hideki
Tajima, Masami
Hishida, Akira
Naganuma, Hideo
机构
[1] Sankyo Co Ltd, Clin Pharmacol & Biostat Dept, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[3] Shitoro Clin, Hamamatsu, Shizuoka 4328067, Japan
[4] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan
关键词
prediction; pharmacokinetics; hemodialysis; end-stage renal disease (ESRD); antibiotic;
D O I
10.1248/bpb.29.1454
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel and convenient method to predict the pharmacokinetics of several kinds of antibiotic agents in patients with end-stage renal disease (ESRD) was examined based on the in vitro extraction ratios and pharmacokinetic parameters in healthy volunteers. The dializability of 17 antibiotic agents in 4% human serum albumin solution were determined using a high-performance hemodialytic membrane for clinical use. We assumed that the off-hemodialysis clearance approximated the non-renal clearance, while the on-hemodialysis clearance was considered to be sum of the off-hemodialysis clearance and the hemodialytic clearance. The estimated on- and off-hemodialysis clearances were compared with the ones observed in ESRD patients. In order to confirm the method prospectively, an in vivo pharmacokinetic study was performed in dogs with mercury chloride-induced experimental renal failure. The in vitro extraction ratios of 9 beta-lactams were broadly ranged from 10.9 to 75.6% depending on their physicochemical properties. In contrast, those of the other antibiotics were consistent with their chemical classes: 60.5-63.2% for fluoroquinolone, 48.8-51.1% for aminoglycoside and 18.7-25.6% for glycopeptide. Both the estimated on- and off-hemodialysis clearances of the 17 antibiotics coincided well with the observed values in the literature, regardless of their physicochemical and pharmacokinetic properties. The validity and applicability of this method to three cefems, cefmetazole, cefotaxime and cefoperazone, was prospectively confirmed in the animal study. In conclusion, this new method enables the prediction of the on- and off-hemodialysis clearances of several kinds of antibiotics in ESRD patients from minimal information of their pharmacokinetics in healthy subjects and their in vitro dializability.
引用
收藏
页码:1454 / 1459
页数:6
相关论文
共 50 条
  • [21] Pharmacokinetics, safety and tolerability of serelaxin in patients with severe renal impairment or end-stage renal disease
    Pang, Y. Yinuo
    Dahlke, M.
    Halabi, A.
    Canadi, J.
    Tsubouchi, C.
    Machineni, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 89 - 89
  • [22] Alteration of thiamine pharmacokinetics by end-stage renal disease (ESRD)
    Frank, T
    Bitsch, R
    Maiwald, J
    Stein, G
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1999, 37 (09) : 449 - 455
  • [23] HCV in patients with end-stage renal disease
    Okoh, Emuejevoke J.
    Bucci, Jay R.
    Simon, James F.
    Harrison, Stephen A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08): : 2123 - 2134
  • [24] Correlates for end-stage renal disease patients
    Yavuz, N
    Karatas, M
    Kilinç, S
    SCANDINAVIAN JOURNAL OF CARING SCIENCES, 2000, 14 (03) : 179 - 183
  • [25] Tuberculosis in patients with end-stage renal disease
    Fang, HC
    Lee, PT
    Chen, CL
    Wu, MJ
    Chou, KJ
    Chung, HM
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2004, 8 (01) : 92 - 97
  • [26] Hypertension in end-stage renal disease patients
    Zager, P
    Nikolic, J
    Raj, DSC
    Tzamaloukas, A
    Campbell, M
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2000, 9 (03): : 279 - 283
  • [27] Cardiovascular disease in end-stage renal disease patients
    Collins, AJ
    Li, SL
    Ma, JZ
    Herzog, C
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S26 - S29
  • [28] Hepatitis in patients with end-stage renal disease
    Huang, CC
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1997, 12 (9-10) : S236 - S241
  • [29] End-stage renal disease in patients with Fabry disease
    Obrador, GT
    Ojo, A
    Thadhani, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (06): : S144 - S146
  • [30] PHARMACOKINETICS OF KETOPROFEN IN PATIENTS WITH END-STAGE RENAL-FAILURE
    GRUBB, NG
    RUDY, DW
    HALL, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 222 - 222